Can testosterone replacement therapy worsen keratosis pilaris in a male patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Testosterone Replacement Therapy and Keratosis Pilaris

Testosterone replacement therapy can worsen keratosis pilaris, though this is an uncommon dermatologic side effect. While acne is the most frequently reported skin complication of TRT, there is documented evidence of testosterone-induced generalized keratosis pilaris.

Evidence for Dermatologic Effects

The FDA-approved labeling for testosterone identifies skin and appendage effects including "hirsutism, male pattern of baldness, seborrhea, and acne" 1, but does not specifically list keratosis pilaris. However, a 2023 case report documented the first instance of generalized keratosis pilaris induced by testosterone injections in a 13-year-old boy with CHARGE syndrome 2. This represents direct evidence that testosterone can trigger or worsen this condition.

A comprehensive 2026 scoping review of dermatological adverse effects found that:

  • Acne is the most common skin side effect (0.6%-9.1% of patients) 3
  • Abnormal hair growth occurs in up to 5.3% of patients 3
  • Injectable formulations carry higher rates of dermatologic reactions than topical or oral preparations 3

Clinical Implications

Risk Assessment

The mechanism likely relates to testosterone's effects on follicular keratinization and sebaceous gland activity. Since keratosis pilaris fundamentally involves follicular hyperkeratosis with abnormal desquamation 4, 5, and testosterone stimulates follicular activity, the connection is biologically plausible.

Formulation Considerations

If TRT is medically necessary despite keratosis pilaris concerns, consider topical or oral formulations over injectable testosterone, as injectable forms demonstrate higher rates of cutaneous complications 3. The 2004 NEJM guidelines note that intramuscular injections produce supraphysiologic testosterone peaks that may exacerbate androgen-dependent skin effects 6.

Management Strategy

If keratosis pilaris worsens on TRT:

  • First-line topical keratolytics (alpha hydroxy acids, beta hydroxy acids, or urea) can manage symptoms 4
  • Consider dose reduction or formulation change
  • Monitor for other dermatologic effects (acne, hirsutism) which are more common

Important Caveats

The evidence for testosterone-induced keratosis pilaris is limited to case reports, making it difficult to quantify true incidence. Most dermatologic studies of TRT focus on acne rather than keratosis pilaris 3. The condition may be underreported since it's often considered cosmetically bothersome rather than medically significant, though it can substantially impact quality of life 4.

The decision to continue or initiate TRT should weigh the established benefits for hypogonadism (improved sexual function, bone density, muscle mass, mood) 7 against the relatively minor but real risk of worsening keratosis pilaris, particularly if the patient already has this condition or risk factors (dry skin, atopic dermatitis, adolescence) 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.